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Abstract 
Background 
In the UK, pharmacist independent prescribers (PIPs) can prescribe for any condition within 
their clinical competence including systemic anti-cancer therapy (SACT). Competency 
frameworks have been developed but contain little detail on the patient assessment skills 
(PAS) PIPs require to prescribe SACT with concern in literature over current training on 
these skills. 
Aim 
To gain consensus on the PAS required by PIPs prescribing SACT for genitourinary [GU] 
cancer (prostate & renal) and lung cancer across NHS Scotland. 
Method 
Two phases were performed to generate PAS consensus. Initially, the Nominal Group 
Technique (NGT) was performed within a local cancer network by discussion and participant 
ranking within GU and lung cancer multi-disciplinary teams (MDTs). Where consensus was 
achieved, PAS were carried forward to try to achieve national (NHS Scotland) consensus  
using a two-round Delphi questionnaire. 
Results 
Of the 27 PAS, consensus was gained for 21 and 23 PAS in the GU and lung NGT groups 
respectively. Within the GU (n=23) and lung (n=18) national groups, 13/21 and 18/23 PAS 
were agreed as required for a PIP to prescribe SACT in GU and lung cancer respectively. 
Eight common PAS were identified as core skills. Reasons for not reaching consensus 
included PIP competence, knowledge, skills and the roles and responsibilities of PIPs within 
the MDT.  
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Conclusion 
We identified the core and specific PAS required to prescribe SACT within two tumour 
groups. Further work is necessary to develop PAS competency frameworks, training and 
assessment methods and to redefine the roles of PIPs within the MDT.   
Keywords: Pharmacist independent prescribing, Systemic anti-cancer therapy, patient 
assessment skills.  
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1.  Introduction 
Non-medical prescribing has developed significantly in the last two decades, with several 
countries promoting this new role.1,2,3 Pharmacists in the United States of America, 
Canada, New Zealand and the UK can now become independent prescribers but, a variety 
of different prescribing models exist with some countries only allowing pharmacists to 
prescribe under clinician supervision and others enabling pharmacists to prescribe without 
these additional restrictions.2,3,4  
 
In the UK, pharmacists can prescribe independently for any undiagnosed or diagnosed 
condition within their competence.5  Around 8% (3,944) of registered pharmacists in the 
UK are non-medical prescribers (NMPs).6 Currently, training for pharmacist independent 
prescribers (PIPs) consists of university based training followed by observational learning 
and practice within the trainee’s chosen therapeutic area. Competency is determined by a 
designated medical practitioner who supervises this practice.5 The Scottish Government’s 
strategy ‘Prescription for Excellence’ states that by 2023, every pharmacist will be a PIP.7 
Furthermore, Scottish Government guidance of the Safe use of Systemic Anti-Cancer 
Therapy (SACT) states that NMPs can prescribe SACT provided they have been 
appropriately trained and deemed competent.8  
 
To support PIPs in this new role, a small number of prescribing frameworks have been 
developed in the UK. In 2016, the Royal Pharmaceutical Society (RPS) published a 
competency framework for all prescribers9 and the British Oncology Pharmacy 
Association (BOPA) published a chemotherapy PIP prescribing competency 
framework.10 The BOPA framework is based on the UK Medical Oncology Curriculum 
which is used to train registrars prescribing SACT and is approved by the Royal College 
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of Physicians and the Postgraduate Medical Education and Training Board.11 
Furthermore, the West of Scotland Cancer Network (WoSCAN) recently published a 
NMP competency framework and service development tool which suggests a tiered 
approach to PIP training with the use of training tools such as case-base discussions to 
assess competency.12   
 
The BOPA and WoSCAN frameworks provide guidance for PIPs prescribing SACT 
however they do not include the patient assessment skills (PAS) [e.g. physical 
examination, vital signs (blood pressure (BP), respiratory rate (RR)] that a PIP may 
require to prescribe SACT, only stating the PIP should have the ‘Ability to prescribe and 
order systemic therapies following assessment of the patient and relevant laboratory 
investigations, using appropriate systems defined by the local authorities.’10 The PAS 
training required for PIPs to prescribe SACT should be defined locally.  
 
Review of the literature highlights a lack of information in the patient assessment skill 
training required for PIPs. It does however highlight concerns both by PIPs and other 
healthcare professionals over a PIPs current ability to fully clinically assess patients and 
the current training in place.13 Current studies assessing pharmacists prescribing in SACT 
clinics demonstrate their benefit to patients in terms of reducing clinic waiting times, 
improving medicines compliance and management of adverse reactions but do not review 
PIP training.14,15  
 
One previous study attempted to define a patient assessment competency framework for 
PIPs prescribing SACT via an electronic questionnaire which was distributed to multi-
disciplinary teams (MDTs) across NHS Scotland [98/240 responses (40.8%)]. Of the 27 
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PAS included in the questionnaire, only 12 achieved agreement.16 Reasons for lack of 
agreement included differences in current PIP practice between networks regions and a 
lack of information on training requirements.16 Furthermore, the study did not use a 
validated consensus method and included all cancer types, each of which may require 
different patient assessment skills. For this reason, this study has focussed on two tumour 
groups, genitourinary (GU) cancer (renal and prostate) and lung cancer, selected due to 
disease burden and service pressures. The study aim was to gain consensus on the PAS 
required by PIPs in GU and lung cancer. 
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2. Methods 
2.1 Design 
This two-phase study used a Nominal Group Technique (NGT) to obtain consensus within 
South East Scotland Cancer Network (SCAN) on the PAS a PIP requires to prescribe SACT, 
followed by a two-round Delphi questionnaire to gain consensus across NHS Scotland.  
2.2 Setting 
The study was conducted within the three regional cancer networks within NHS Scotland: 
SCAN, WoSCAN and North of Scotland Cancer Network (NoSCAN). 
2.3 Phase 1: Nominal Group Technique 
2.3.1 Inclusion criteria & participant recruitment 
Within SCAN, each tumour specific MDT includes consultants, a rotational registrar, clinical 
nurse specialists and pharmacist prescribers.  Members of the SCAN GU (n=9) and lung 
(n=10) MDT were invited to participate through an email comprising of an invitation letter, 
participant information sheet and consent form. From respondents, a convenience sample of a 
range of professions was determined through availability.  
2.3.2 Data generation 
Consensus methods such as the NGT and the Delphi technique are commonly used in 
medical research to gather information and develop guidelines in areas where there is little 
published research through consultation between a group of experts.17,18,19 It was decided to 
use the NGT within SCAN to enable face-to-face discussion, generation of ideas and gain 
consensus on a list of PAS developed specifically for each tumour group.17  This standardised 
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process was followed for each NGT (Figure 1). A 5-point Likert scale was used as this is a 
common scale used in consensus methods. 19, 20  
  
Figure 1: Nominal Group Technique process for each group 
2.3.3 Data analysis 
Consensus was achieved if at least 70% of the group scored an individual skill as 1 or 2 (for 
disagreement i.e. skill not required) or 4 or 5 (for agreement i.e. skill is required).21,22 The 
skills that achieved 70% consensus were used to populate the Delphi for each tumour group. 
Skills which did not achieve consensus were removed as lack of local consensus on a certain 
skill was thought to be unlikely to achieve national consensus. Furthermore, comments for 
skills where there was a mixed response were reviewed to identify reasons for non-consensus.  
 
Silent Generation Phase
Participants sent a NGT workbook including  list of patient 
assessment skills (n=27) generated from previous work,15
summary of existing training courses and open questions to 
consider before NGT. Time was also given during the session to 
review these. 
Round Robin
Each member of the group given an opportinuty to express 
their opinion on each skill 
Clarification
Time given for clarification on certain points already discussed
Ranking
Participants asked to silently rank each PAS using a 5-point 
Likert scale (5 being strongly agree and 1 strongly disagree) 
Discussion and Re-ranking
Group results collated and verbally fed back to the group. 
Participants given an opportunity to change their rankings 
individually. Final rankings collected for analysis. 
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2.4 Phase 2: Delphi technique  
2.4.1 Inclusion criteria & participant recruitment 
Members of the SCAN, WoSCAN and NoSCAN MDTs (consultants, registrars, 
pharmacists/nurses (prescribers and non-prescribers)) for GU (n=30) and lung (n=43) were 
invited to participate in the study.  
2.4.2 Data generation  
The results from each nominal group were reviewed and developed into a questionnaire 
consisting of a set of statements (the PAS) for each tumour group (using the online Qualtrics 
Survey programme ®). The Delphi technique was then used to obtain national consensus 
through multiple questionnaire rounds (Figure 2). Participants were asked to rank the 
statements using a 7-point Likert scale (7 being strongly agree and 1 strongly disagree).19 A 
free text box for participant comments was also added to the questionnaire. Participants were 
asked in the workbook (NGT) and questionnaire (Delphi) to consider the PAS required by 
PIPs working with the support of MDT when assessing patients and prescribing continuation 
of SACT. 
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Figure 2: Delphi process for each national MDT group  
 
2.4.3 Data Analysis 
Setting consensus varies widely between studies; percent agreement appears the most 
common definition of consensus with a range of set values between studies (70-90%). 23,24 
The project team agreed that consensus would be reached if ≥70% of the scores fall within 3 
points of each end of the scale (1-3 for disagreement and 5-7 for agreement).  The median 
was also calculated for each statement after the first round questionnaire to inform the second 
round participants of the group’s median response.  Statements which achieved consensus 
Pilot of questionnaire to n=6 (3 pharmacists, 2 nurses, 1 
registrar) and minor adjustments  made to wording and 
format .
FIRST ROUND
Distribution of questionnaire via email with information sheet . 
Consent included in questionnaire.
Reminder email sent after one week. 
ANALYSIS
Results of first round questionaire analysed. Patient assessment 
skills which obtained consensus removed from questionnaire. 
SECOND ROUND
Re-distribution of questionnaire with skills which did not obtain 
consensus (<70%) with previous median and comments from 
group.
Reminder email sent after one week.
ANALYSIS
Results of second round questionnaire analysed. 
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(≥70% agree or disagree) were removed before the second round Delphi. Results from the 
second round were analysed via the same method. 
2.5 Research ethics  
 This project was a service development involving NHS employees only therefore submission 
to the NHS Research Ethics Committee and Research and Development office was not 
required.  Approval was obtained from the local pharmacy Quality Improvement Team. 
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3.0 Results 
3.1 Phase 1: Nominal Group Technique 
Six specialists in renal and prostate cancer participated in the GU nominal group (two 
consultants, one registrar, two nurse specialists and one pharmacist). Consensus was reached 
for 21/27 (78%) PAS, nine were considered required for PIPs and 12 were considered not 
required . Six PAS did not achieve consensus. Five specialists in lung cancer participated in 
the lung nominal group (one consultant, one registrar, two nurse specialists and one 
pharmacist). Consensus was reached for 23/27 (85%) PAS, 15 were considered required for 
PIPs and eight were considered not required. Two PAS were considered irrelevant to the 
tumour group and two did not achieve consensus (Table 1). The skills which did not achieve 
consensus are summarised below. 
GU group 
Interpretation of computerised tomography (CT) scans 
Some felt that with specific training the PIP would be able to interpret a CT scan as part of 
advanced practice whereas others thought it more appropriate that a clinician review the scan.  
“Will need discussion in some cases. Back to cons clinic for review.” GU Consultant 1 
“May be able to with training in more advanced practice.” GU Consultant 2 
Examination of oral mucosa, hands, legs/feet, skin and neurotoxicity 
A number of participants felt that as clinical problems with these areas are rare in GU 
cancers, they would always require clinician review. However, some felt these skills could be 
taught with adequate training. 
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“All these skills are rare in these tumour groups so would benefit from medic review. Not 
relevant to this cancer therefore always seek advice.” GU Consultant 2 
Lung group 
Lymph node palpation  
Some felt that this skill was rarely required however others felt like it could be a skill 
developed as part of advanced practice.  
“Felt overall not appropriate and rarely required for a pharmacist to do this but with time 
might be something we could look at.” Lung Consultant 1 
Interpretation of urinalysis  
The majority of the group did not feel this skill was necessary but the nurse specialists thought it may 
be useful in detecting diabetes. 
 “Rarely required but may be useful for diabetes – some new TKIs can cause this” Lung 
Nurse 1 
 
 
 
 
 
 
 
14 
 
Table 1: Group NGT results for GU team (n=6) and Lung team (n=5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Phase 2: Delphi Technique 
Category Skill GU 
group 
Lung 
group 
 
 
Common 
SACT toxicities  
Assessment of performance status ● ● 
Assessment of general appearance and 
well being 
● ● 
Assessment of nausea and vomiting ● ● 
Assessment of diarrhoea ● ● 
 
 
 
 
Clinical 
examination 
skills 
Examination of oral mucosa and 
tongue 
▲ ● 
Examination of hands ▲ ● 
Examination of legs, ankles and feet ▲ ● 
Examination of skin (e.g. rash, PPE) ▲ ● 
Assessment of neurotoxicity ▲ ● 
Assessment of arthralgia ○ - 
Measuring and interpreting vital signs 
(BP, HR, temperature, RR) 
● ● 
Basic chest examination ○ ● 
Lymph node palpation ○ ▲ 
Abdominal examination ○ ○ 
Complications 
of 
cancer/SACT 
Identifying signs/symptoms of spinal 
cord compression 
● ● 
Identifying signs/symptoms of 
neutropenic sepsis 
● ● 
 
 
Interpretation 
of clinical tests 
Interpretation of thyroid function tests 
results 
● - 
Interpretation of pulmonary function 
tests results 
○ ○ 
Interpretation of tumour markers  ● ○ 
Interpretation of electrocardiogram 
results 
○ ● 
Interpretation of  left ventricular 
ejection fraction reports e.g. 
ECHO/MUGA 
○ ○ 
Interpretation 
of clinical 
reports 
Interpretation of urinalysis results ○ ▲ 
Interpretation of CT reports ▲ ○ 
Interpretation of  x-ray reports ○ ○ 
Interpretation of ultrasound reports ○ ○ 
Emotional and 
holistic needs 
assessment 
Assessment of emotional needs and 
psychological impact of treatment 
○ ● 
Holistic needs assessment ○           ○ 
Key:  
● Agree (≥70% of participants voted agree or strongly agree)  
○ Disagree (≥70% of participants voted disagree or strongly disagree) 
▲ No consensus 
 - considered irrelevant to tumour group 
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3.2 Phase 2: Delphi Questionnaire  
Of the 30 GU cancer specialists invited to participate, 23 (77%) provided consent and 
completed the first round Delphi (Table 2 and Figure 3). Consensus (≥70% of participants 
agreed or disagreed) was achieved for 13/21 PAS included in the questionnaire (Table 3). 
The eight skills which did not achieve consensus were carried forward to the second round 
Delphi questionnaire in combination with the median group result and comments from the 
group.  In the second round Delphi, 20/23 (86.9%) participants responded and consensus was 
gained for a further two skills. In total, 13 PAS were agreed as required for a PIP to have to 
prescribe SACT in GU cancer.  
Of the 42 lung specialists invited to participate, 18 (43%) provided consent and completed 
the first round Delphi (Table 2 and Figure 3). Consensus (≥70% of participants agreed or 
disagreed) was achieved for 16/23 PAS included in the questionnaire (Table 3). In the second 
round Delphi, 12/18 (66.7%) participants responded and a further two skills gained consensus 
(Table 3). In total, 18 PAS were agreed as required for a PIP to have to prescribe SACT in 
lung cancer. Comparing the results for both tumour groups, eight PAS gained consensus as 
required for a PIP between both tumour groups and were thus defined as core PAS.  
Comments from both groups on why they did not change their opinion are outlined in Table 
4. From the comments provided, it was unlikely consensus on further PAS would be achieved 
therefore a third round Delphi was not completed. The main reasons for not reaching 
consensus were around PIP competence, knowledge and skills, and the roles and 
responsibilities of PIPs within the MDT (Table 4). The PAS agreed as required were divided 
into core (required for all tumour groups) and tumour specific (Figure 4).   
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Table 2: Participant demographics of the national Delphi questionnaire round 1 
Region GU group n=23(n, %) Lung group n=18(n, %) 
SCAN  9(39) 5(28) 
WoSCAN  9(39) 11(61) 
NoSCAN  5(22) 2(11) 
   
Profession   
Consultant 9(39) 5(28) 
Registrar 2(9) 2(11) 
Pharmacist (prescriber) 9(39) 8(44) 
Pharmacist (non-prescriber) - 1(6) 
Nurse (prescriber) 2(9) - 
Nurse (non-prescriber) 1(4) 2(11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Number of participants from each MDT (GU and Lung) from each cancer network (SCAN, 
WoSCAN and NoSCAN) who were invited to participate and responded to the Delphi questionnaire.  
 
Delphi  
questionnaire 
participants 
SCAN 
Invited 
GU= 9 Lung=13 
 
 
Delphi round 1 
Responded 
GU=9(100%) 
Lung= 5(38%) 
Delphi round 2 
Responded 
GU=8 (89%) 
Lung= 5 (38%) 
WoSCAN 
Invited 
GU= 13 Lung=25 
 
 
Delphi round 1 
Responded 
GU=9 (69%) 
Lung= 11(44%) 
Delphi round 2 
Responded 
GU= 7 (53%) 
Lung= 5 (20%) 
NoSCAN 
Invited 
GU= 8 Lung=5 
 
 
Delphi round 1 
Responded 
GU=5 (63%) 
Lung= 2 (40%) 
Delphi round 2 
Responded 
GU= 5 (63%) 
Lung= 2 (40%) 
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Table 3: Results collated from round 1 and 2 of the Delphi questionnaire for GU team (n=23) and 
lung team (n=18). 
Category Skill GU 
group 
Lung 
group 
 
Common 
SACT toxicities  
Assessment of performance status ● ● 
Assessment of general appearance, 
(lung cancer symptoms) and well 
being 
● ● 
Assessment of nausea and vomiting ● ● 
Assessment of diarrhoea ● ● 
 
 
 
 
Clinical 
examination 
skills 
Examination of oral mucosa and 
tongue 
- ● 
Examination of hands - ● 
Examination of legs, ankles and feet - ● 
Examination of skin (e.g. rash, PPE) - ● 
Assessment of neurotoxicity - ● 
Assessment of arthralgia ● - 
Measuring and interpreting vital signs 
(BP, HR, temperature, RR) 
● ● 
Basic chest examination ▲  ●* 
Lymph node palpation  ○* - 
Abdominal examination  ○* ▲ 
Complications 
of 
cancer/SACT 
Identifying signs/symptoms of spinal 
cord compression 
● ● 
Identifying signs/symptoms of 
neutropenic sepsis 
● ● 
 
 
Interpretation 
of clinical tests 
Interpretation of thyroid function tests 
results 
● - 
Interpretation of pulmonary function 
tests results 
▲ ▲ 
Interpretation of tumour 
markers/mutational status  
● ● 
Interpretation of electrocardiogram 
results 
▲ ● 
Interpretation of  left ventricular 
ejection fraction reports e.g. 
ECHO/MUGA 
▲  ●* 
Interpretation 
of clinical 
reports 
Interpretation of urinalysis results ● - 
Interpretation of CT reports - ▲ 
Interpretation of  x-ray reports ● ▲ 
Interpretation of ultrasound reports ▲ ▲ 
Emotional and 
holistic needs 
assessment 
Assessment of emotional needs and 
psychological impact of treatment 
● ● 
Holistic needs assessment ▲           ● 
Key:  
● Agree (≥70% of participants voted agree, somewhat agree or strongly agree)  
○ Disagree (≥70% of participants voted disagree, somewhat disagree or strongly disagree) 
▲ No consensus 
 - considered irrelevant to tumour group 
 
*Skills which achieved consensus following the 2nd round.  
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Table 4: Comments on skills which did not gain consensus following the Delphi 
Comments 
Basic chest examination and abdominal examination 
 
“There may be the need to undertake these examinations, but I am still of the opinion......it'd be 
most appropriate to refer to a medic…I think that it's important to recognise our own strengths as 
well as those of other members of the team.” GU Pharmacist 3 
 
“Having completed university level examination skill course and find once a practitioner has built 
confidence in their skills it is useful and allows more independent practice.” GU Pharmacist 5 
 
“I think if you are examining a patient and prescribing SACT for lung cancer then you should be able 
to examine a chest and abdo. How can patients have confidence in us as practitioners if we refer to 
nurses or medics?” Lung Pharmacist 6   
 
“On reflection a basic/limited examination skill would be helpful in recognising abnormality and 
escalating.” Lung Registrar 1    
 
Interpretation of ECG and left ventricular ejection fraction reports e.g. ECHO/MUGA 
 
 “… if you are rarely using a skill it is difficult to be competent. I would never feel competent to 
interpret an ECG but have been successfully prescribing in a Renal Oncology setting for several 
years.” GU Pharmacist 6    
 
“I would expect a PIP to interpret at QTc, but not more subtle lead changes. Similarly, ability to 
understand a low ejection fraction on echo is critical to safe prescribing of some drugs. “ GU 
Consultant 2 
Interpretation of x-rays, ultrasounds and CT scans 
     
“We alternate between chest x-rays and CT scans for our oral lung SACT, I think if you are in 
consultation with the patient and reviewing them you need to be able to interpret an x-ray and 
match these to clinical findings….” Lung Pharmacist 6 
 
“The pharmacist IP should be aware of the need for imaging to monitor response to treatment and 
liaise with medical staff to ensure imaging is done at an appropriate time and the results have been 
reviewed by medical staff before continuing treatment.” Lung Consultant 3 
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Figure 4: Summary of the PAS which were agreed as required for a PIP to have to prescribe SACT 
grouped as core skills across tumour groups and tumour specific skills.  
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4. Discussion 
Key findings 
This study explored with clinicians from two distinct tumour groups the PAS required for a 
PIP to prescribe SACT therapy and identified a group of core skills (n= 8) and PAS specific 
to GU cancers (n=5) and lung cancers (n=10). Examples of core skills included toxicity 
assessment and vital sign measurements whereas tumour specific skills appeared specific to 
the disease state, for example basic chest examination in lung cancer and checking prostate-
specific antigen (PSA) as a tumour marker in prostate cancer. These findings could form the 
basis for the development of a competency framework for PIP SACT prescribing moving 
forward. 
There were some differences in the number of agreed PAS between the NGT and Delphi 
questionnaire. These were considered a reflection of variation in local versus regional 
practice rather than the consensus method used. The role of PIPs as SACT prescribers is well 
established in WoSCAN and NoSCAN. PIPs that work in these clinics are experienced 
practitioners and may reflect PIPs in an advanced prescriber role. Their ability to perform 
PAS competently is likely to have developed over time and with experience demonstrating 
that learning these skills is achievable. Having experienced this more advanced PIP role, 
clinicians and nurses within these networks will be more aware of the potential abilities of 
PIPs. In contrast, SCAN has no PIPs prescribing SACT therefore the practice of other regions 
could be used as a basis for training of new PIPs.  
A small number of PAS did not achieve consensus following the Delphi questionnaire. The 
themes arising from the comments on these skills centred around development of knowledge 
and skills and maintaining competence, specifically for skills that would be used infrequently.  
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Current pharmacist undergraduate and PIP postgraduate training programmes contain 
minimal patient assessment skill training.7 Recently NHS Education for Scotland (NES) 
developed a number of clinical patient assessment training programmes for cardiovascular 
and respiratory disease, however these would not encompass the skills required to prescribe 
SACT.25 Therefore, additional training programmes would be required to enable PIPs to 
improve their knowledge and develop PAS for prescribing SACT. However, some of the 
participant comments suggested that some skills cannot be taught and can only be developed 
through experiential learning. A number of participants suggested that certain advanced skills 
(e.g. interpretation of CT/ultrasound scans) could be developed as part of a more advanced 
PIP role. 
Confidence in a PIP’s ability to carry out these PAS was also a key theme. Despite being 
aware of the advanced roles of PIPs in other networks, participants who did not have 
experience carrying out PAS within their own network were not willing to change their 
opinion on certain PAS during the Delphi questionnaire. Most commented that they did not 
feel confident in some PAS. Confidence in ability to carry out clinical assessment skills and 
in maintaining competence has also been highlighted in the literature as a barrier to PIPs in 
new prescribing roles.26 
Roles and responsibilities of each member of the MDT was another identified theme in both 
tumour groups. Even if a PIP has been trained in a certain skill, they may not be the best 
suited member of the MDT to carry out this assessment or the need for the skill is rare. For 
example, the lung group could not agree on the requirement for a PIP to interpret a report of a 
CT scan or x-ray. Some felt that although it was vital for PIPs to have an understanding of 
these types of reports to understand disease progression, it is more appropriate for a medical 
member of staff to interpret these, particularly for complex cases. For some of the PAS which 
did not achieve consensus in either tumour group, doctors and PIPs considered it more 
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appropriate to refer to a medical member of staff. This was a common comment from both 
PIPs and doctors and could be related to the perceived role of PIPs within the MDT as an 
expert in medicines rather than in clinically examining patients; a role more common of 
doctors and nurses.  
Strengths and limitations  
Consensus methods such as the NGT and Delphi questionnaire enable generation of ideas 
followed by consensus between a group of specialists and development of guidance where 
there is little published research.17,18  The Delphi questionnaire enables consultation of a 
larger number of specialists on a national level. In this study, the two rounds enabled further 
consensus to be achieved as participants were able to review other participant comments and 
the group median before re-ranking the skills.19 Differences between the NGT and Delphi 
groups could be attributed to the fact that the NGT involves a face-to-face discussion whereas 
the Delphi is anonymous, allowing opinions to be expressed more freely. 
Setting consensus varies widely between NGT and Delphi consensus studies; percent 
agreement appears the most common definition of consensus with a range of set values 
between studies (70-90%).23,24 Consensus was set at 70% in this study. This enabled 
consensus to be achieved in an area where there is currently a wide variety of practice. 
Reporting the median to participants allowed them to consider the opinion of the group in 
combination with the group comments before making a decision on their second round 
ranking. 
During the NGT, there was difficulty in recruiting a sufficient number of people due to 
availability for face-to-face discussions and ensuring that an adequate range of professions 
were included. However, sample sizes for the Delphi questionnaire were adequate. Sample 
sizes for Delphi participants vary widely in literature, ranging from 10 to hundreds of 
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participants with no widely accepted minimal sample size for this consensus method. The 
sample size should be as deemed appropriate by the investigator and based on availability of 
participants.27 There was a good response rate from the GU group nationally (n=23/30, 
76.7%), improving the validity of the findings. Although there was a lower response rate for 
the lung group (n=18/42, 43%), this higher than observed in other studies. 19,26  
A limiting factor to low response rate for the lung group may have been the small number of 
PIPs currently prescribing within lung cancer meaning that the MDTs did not feel able to 
sufficiently complete the questionnaire as they had little, if any exposure to PIPs in this 
prescribing role. Whereas within the GU group, there are multiple PIPs within WoSCAN and 
NoSCAN who were  established prescribers. Furthermore, the response rate to the second 
round Delphi was not 100% in each group, 20/23 (87%) in the GU group and 12/18 (66.7%) 
in the lung group, which limits the validity of the second round results. A reason for this may 
include that participants did not want to change their responses or had developed responder 
fatigue.  
Within the GU national group there was a relatively equal spread of participants from each 
regional network meaning that the national group can be said to have been representative of 
all NHS Scotland cancer networks, with no single network dominating the consensus process. 
Within the lung group there was a higher portion of responders from WoSCAN (61%) 
however this did not appear to affect the ability to obtain consensus. 
Policy, practice and research implications 
There is currently a lack of guidance on the PAS training required for PIPs. Current literature 
assessing PIPs prescribing in SACT clinics demonstrates their value in these clinics but does 
not consider how PIPs may be trained in PAS to prescribe SACT safely.14,15 In addition, 
concerns have been highlighted by various members of the MDT over a PIP’s ability to fully 
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clinically assess patients and the current training in place.13 Prescribing frameworks 
developed by the RPS, BOPA and WoSCAN contain minimal detail on PAS.9,10,12 This 
means that further work is required to develop current PIP prescribing frameworks and 
policies to align with current practice of PIPs as prescribers in oncology and allow expansion 
of this role in other cancer networks.   
This study has identified the PAS required for PIPs to prescribe SACT in two tumour groups. 
Further work will be required to define the evidence required by a PIP to demonstrate 
competence for each PAS. External training programmes may be able to provide baseline 
training in certain skills but it is likely that as certain skills are cancer specific and can often 
be quite complex, experiential learning may be required to fully develop these skills.  
A recent study developed a competency framework for PIPs prescribing in heart failure. It 
used the RPS Foundation and Advanced Pharmacy Frameworks as structure in development 
of their framework to make it more widely applicable in the UK.28,29,30 It may be that these 
frameworks could be used as guidance in combination with the BOPA prescribing framework 
to further develop competency frameworks to reflect the identified PAS. The next steps 
following this study will be to liaise with the Scottish Oncology Pharmacy Practice Group 
(SOPPG) and BOPA to integrate the identified PAS into current frameworks and develop 
training tools to suit all NHS Scotland cancer networks.  
Further work will also be required to identify the method of assessment for competence in 
these frameworks. This could be in the form of observational assessment by a medical or 
experienced member of the team - these would need to be defined in a national framework. 
The recent framework developed by WoSCAN suggested that training tools such as case 
based discussion and mini-clinical evaluation exercise could also be used as evidence in the 
25 
 
training of PIPs.12  Frameworks will be required to be developed and piloted for other tumour 
groups in order to identify which tumour specific PAS may be required for that tumour type.  
Further work may also be required to identify the enablers and barriers to PIPs prescribing 
SACT and performing PAS to determine why there was a perceived reluctance to develop 
advanced skills. Overcoming barriers such as confidence in a PIP’s own ability will hopefully 
aid new prescribers and current prescribers looking to develop their prescribing role.  
Conclusion 
This study defined the PAS a PIP requires to prescribe SACT within two tumour groups. It 
was evident from this study that current practice of PIPs working as part of the oncology 
MDTs varies widely across NHS Scotland cancer networks. As there are currently no PIPs 
prescribing SACT in SCAN, practice within other networks should be considered when 
developing national frameworks. Further work will be required to establish the training tools 
required to support this development in knowledge and skills and to explore how competence 
will be assessed. In addition, this work will need to extend to other tumour types to fully 
define the roles and responsibilities of a PIP within the oncology MDT.
26 
 
Acknowledgements 
Thank you to all members of the MDT within SCAN, WoSCAN and NoSCAN who 
participated in the study.   
 
27 
 
 
References 
                                                          
1 George J, MacLure K, Stewart D. Educating non-medical prescribers. British Journal of 
Clinical Pharmacology Feb 2012; 74(4): 662-667.  
 
2 McCaig D, Stewart D, Tonna AP. An international overview of some pharmacist 
prescribing models. Journal of the Malta College of Pharmacy Practice 2008; 14:20-26. 
 
3 Raghunandan R, Smith A, Tordoff J. Non-medical prescribing in New Zeland: an overview of 
prescribing rights, service delivery models and training. Therapeutic advances in Drug 
Safety. 2017; 8(11): 349-360  
 
4 Abuzour AS, Cope LC, Tully MP. Nonmedical prescribing: where are we now? Therapeutic 
Advances in Drug Safety 2016; 7(4): 165–172. 
 
5 Department of Health.  Improving Patients’ Access to Medicines: A Guide to Implementing 
Nurse and Pharmacist Independent Prescribing within the NHS in England [Online].  
 
http://webarchive.nationalarchives.gov.uk/20130124072757/http:/www.dh.gov.uk/prod_cons
um_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4133747.pdf (2006, 
accessed November 2017)  
 
6 General Pharmaceutical Council. Prescriber’s Survey Report. 
https://www.pharmacyregulation.org/sites/default/files/gphc_prescribers_survey_report.pdf  
(2016, accessed May 2018)  
 
7 Scottish Government.  Prescription for Excellence: A vision and action plan for the right 
pharmaceutical care through integrated partnerships and innovation [Online].   
http://www.gov.scot/resource/0043/00434053.pdf (2013, accessed November 2017) 
 
8 The Scottish Government.  CEL 30: Guidance for the Safe Delivery of Systemic Anti-
Cancer Therapy. [Online]  
http://www.sehd.scot.nhs.uk/mels/CEL2012_30.pdf  
(2012, accessed March 2018) 
 
9 The Royal Pharmaceutical Society. A Competency Framework for all Prescribers.  
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Professio
nal%20standards/Prescribing%20competency%20framework/prescribing-competency-
framework.pdf (2016, accessed March 2018) 
 
10 British Oncology Pharmacist Association and Faculty of Cancer Pharmacy. Oncology 
Pharmacy Non-Medical Prescribing Guidelines. 2016. Version 2.2  
http://www.bopawebsite.org/sites/default/files/publications/BOPA%20Non%20Medical%20
Prescribing%20Guidelines%20v2.2%20Dec%202016.pdf (2016, accessed November 2017) 
 
 
28 
 
                                                                                                                                                                                    
11 Specialty Training Curriculum for Medical Oncology: Joint Royal Colleges of Physicians 
Training Board. 
http://www.jrcptb.org.uk/specialties/medical-oncology   (2017, accessed March 2018) 
 
12 Non-Medical Prescriber Competency framework and Service Development Tool for the 
Prescribing of SACT. West of Scotland Cancer Network. Version 1 April 2018.  
http://www.intranet.woscan.scot.nhs.uk/regional-groups/sact-future-service-delivery/non-
medical-prescribing/  (2018, accessed July 2018) 
13 Abuzour A.S., Lewis P., Tully M. A qualitative study exploring how pharmacist and nurse 
independent prescribers make clinical decisions. Journal of Advanced Nursing 2017;00:1–10. 
 
14 Connor MO. The hospital pharmacist and oral anti-cancer treatment – what is the role 
within a multi-disciplinary team? European Journal of Hospital Pharmacy: Science and 
Practice 2014;21:A44.  
 
15 Duncan N. Evaluating a pharmacist prescriber role in haematology and oncology clinics. 
Journal of Oncology Pharmacy Practice. Conference: 20th Annual Symposium of the British 
Oncology Pharmacy Association, BOPA 2017. 2017. 23(8): 25)  
 
16 Elliott B, Fisher J, Kinnear M, Souter C. Exploring the assessment skills required by 
pharmacist independent prescribers for the safe prescribing of systemic anti-cancer therapy. 
Journal of Oncology Pharmacy Practice. Conference: 20th Annual Symposium of the British 
Oncology Pharmacy Association, BOPA 2017. 2017. 23(8): 45-46.  
17 Harvey N, Holmes CA. Nominal group technique: An effective method for obtaining group 
consensus. International Journal of Nursing Practice 2012;18(2):188-94 
18 Hunter D, Jones J. Consensus methods for medical and health services research. The 
British Medical Journal 1995; 311(7001): 376–380.  
 
19 King M, McMillan SS, Tully MP. How to use the nominal group and Delphi techniques. 
International Journal of Clinical Pharmacy 2016; 38: 655-662.  
 
20 Butow PN, McGregor D, Rankin NM. Adapting the nominal group technique for priority 
setting of evidence-practice gaps in implementation science. BMC Medical Research 
Methodology 2016; 16(1): 110.  
 
21 Bishop C, Pitchforth E, Russell E, Teijlingen EV. Delphi method and nominal group 
technique in family planning and reproductive health research. The Journal of Family 
Planning and Reproductive Health Care 2006; 32(4): 249–252.  
 
22 Leach MJ, Segal L. Patient attributes warranting consideration in clinical practice 
guidelines, health workforce planning and policy. BMC Health Services Research 
2011;11(1):1-8. 
 
 
29 
 
                                                                                                                                                                                    
23 Hsu CC, Sandford. The Delphi Technique: Making Sense Of Consensus. Practical 
Assessment, Research & Evaluation 2007; 12(10)  
  
24 Diamond IR, Grant RC, Feldman BM et al. Defining consensus: A systematic review 
recommends methodologic criteria for reporting of Delphi studies. Journal of Clinical 
Epidemiology 2014; 67(4): 401-409.  
 
25 NHS Education for Scotland. Education and Training: Pharmacy: Clinical Skills courses.   
http://www.nes.scot.nhs.uk/education-and-training/by-
discipline/pharmacy/pharmacists/prescribing-and-clinical-skills/clinical-skills.aspx (Accessed 
July 2018) 
 
26 Stewart DC, George J, Bond CM et al. Views of pharmacist prescribers, doctors and 
patients on pharmacist prescribing implementation. International Journal of Pharmacy 
Practice. 2009; 17:89-94.  
 
 
27 Akins RA, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: 
application of bootstrap data expansion. BioMed Central: Medical Research Methodology 
2005; 5:37.  
 
28 Forsyth P, Warren A, Thomson C et al. A competency framework for clinical pharmacists 
and heart failure. International Journal of Pharmacy Practice. July 2018. 
 
29 The Royal Pharmaceutical Society. Foundation Pharmacy Framework.  
Available at: https://www.rpharms.com/resources/frameworks/foundation-pharmacy-
framework-fpf  (2014, accessed August 2018) 
 
30 The Royal Pharmaceutical Society. Advanced Pharmacy Framework. 2013.  
Available at: https://www.rpharms.com/resources/frameworks/advanced-pharmacy-
framework-apf (2013, accessed August 2018) 
 
